Case - Papulopustular Drug Eruption Due to an Epidermal Growth Factor Receptor Inhibitors, Erlotinib and Cetuximab

	Unregistered User Click here if this is not your Personal Edition
		Contact Us \| Free E-Mail Updates \| Journals \| Register a colleague

Dermatology Other

EXPLORE :

Most Read News

All Webcasts / CME

Warning | Privacy

Recent cases - Dermatology Other

	Something Fishy
	Russell Bodies in a Skin Biopsy: A Case Report
	Yellow Nail Syndrome
	Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
	Complete Remission of Severe Idiopathic Cold Urticaria on Interleukin-1 Receptor Antagonist (Anakinra)

Recent news - Dermatology Other

	Blood Flow Cytometry May Be Preferable Way to Diagnose, Analyse Mycosis Fungoides: Presented at ASCP - (DGDispatch)
	Converting to Sirolimus From Calcineurin Inhibitors Reduces Risk of Skin Cancer in Kidney Transplant Patients: Presented at Renal Week 2009 - (DGDispatch)
	Spinosad Better Than Permethrin for Pediculosis Capitis in Children: Presented at AAP - (DGDispatch)
	Topical Onychomycosis Treatment More Effective Than Oral Treatment : Presented at EADV - (DGDispatch)
	Mycophenolate Mofetil Benefits Patients With Pemphigus Vulgaris: Presented at EADV - (DGDispatch)

Recent webcasts/CME - Dermatology Other

	Advancements in Enzymatic Debridement: Applying Clinical Science to Everyday Applications
	The Prevention and Treatment of Pressure Ulcers
	Contemporary Options for the Management of Scars
	Pediatric and Adolescent Sports-Related Injuries and Ailments
	The Wound Healing Process

personal edition > dermatology other > cases

Cases

E-Mail this case to a colleague

Papulopustular Drug Eruption Due to an Epidermal Growth Factor Receptor Inhibitors, Erlotinib and Cetuximab

Presented by:	Dermatology Online Journal / Jennifer Bragg MD and Miriam Keltz Pomeranz MD
Summary points:	This case report describes two patients who present with papulopustular eruptions -- a 56-year-old receiving cetuximab for metastatic lung cancer and a 53-year-old receiving erlotinib for metastatic rectal cancer. The case describes the findings from bacterial cultures, treatment, and outcomes. The authors discuss the common side effects of epidermal growth factor receptor and the correlation between the presence and severity of eruption and response to treatment.
Accreditation:	Not available
Other:

Additional Information